Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
We are continuing to explore strategic options to maximize value to our shareholders, including a potential development path for avasopasem.
- We are continuing to explore strategic options to maximize value to our shareholders, including a potential development path for avasopasem.
- The Prescription Drug User Fee Act (PDUFA) target date assigned by the FDA for the NDA was August 9, 2023.
- Research and development expenses were $3.2 million in the fourth quarter of 2023, compared to $8.1 million for the same period in 2022.
- General and administrative expenses were $2.0 million in the fourth quarter of 2023, compared to $5.0 million for the same period in 2022.